LAVA Therapeutics N.V. (LVTX)

Market Cap	42.61M
Revenue (ttm)	4.99M
Net Income (ttm)	-28.32M
Shares Out	26.31M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,015
Open	1.600
Previous Close	1.600
Day's Range	1.580 - 1.640
52-Week Range	0.850 - 2.093
Beta	0.49
Analysts	Hold
Price Target	1.58 (-2.47%)
Earnings Date	Aug 13, 2025

About LVTX

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2021
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: LVTX
• Website: https://www.lavatherapeutics.com

Financial Performance

In 2024, LAVA Therapeutics's revenue was $11.98 million, an increase of 77.01% compared to the previous year's $6.77 million. Losses were -$25.11 million, -40.02% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for LVTX stock is "Hold." The 12-month stock price target is $1.58, which is a decrease of -2.47% from the latest price.

Price Target

$1.58

(-2.47% downside)

Analyst Consensus: Hold